Dear IPIX Shareholders,
In just a few short weeks, we will be convening our Brilacidin-Oral Mucositis End-of-Phase 2 regulatory meeting. Success here not only would help us to complete development of the drug, but also to advance other aspects of our clinical pipeline.
We appreciate your support and will keep you apprised of Company developments.
May all the good things of life be yours now and throughout the coming year.